Patton Fund Management Inc. Acquires Shares of 518 Thermo Fisher Scientific Inc. $TMO

Key Points

• Patton Fund Management Inc. has acquired 518 shares of Thermo Fisher Scientific Inc. valued at approximately $210,000 during the second quarter.
• Thermo Fisher reported Q2 earnings of $5.36 per share, beating estimates, with revenue of $10.86 billion, marking a year-over-year increase of 2.9%.
• The company declared a quarterly dividend of $0.43 per share, reflecting an annualized dividend yield of 0.4%, payable on October 15th.

Patton Fund Management Inc. bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 518 shares of the medical research company's stock, valued at approximately $210,000.

A number of other large investors have also added to or reduced their stakes in TMO. Destiny Wealth Partners LLC purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $207,000. BOS Asset Management LLC purchased a new stake in Thermo Fisher Scientific during the second quarter valued at $222,000. Evergreen Private Wealth LLC grew its stake in shares of Thermo Fisher Scientific by 15.7% in the 2nd quarter. Evergreen Private Wealth LLC now owns 12,798 shares of the medical research company's stock worth $5,189,000 after buying an additional 1,740 shares in the last quarter. American National Bank & Trust raised its position in shares of Thermo Fisher Scientific by 74.1% during the 2nd quarter. American National Bank & Trust now owns 249 shares of the medical research company's stock valued at $101,000 after buying an additional 106 shares in the last quarter. Finally, Old North State Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 24.1% in the 2nd quarter. Old North State Wealth Management LLC now owns 804 shares of the medical research company's stock valued at $327,000 after acquiring an additional 156 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $484.70 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The stock has a market cap of $183.03 billion, a price-to-earnings ratio of 28.03, a price-to-earnings-growth ratio of 2.51 and a beta of 0.75. The firm has a 50-day moving average of $478.98 and a two-hundred day moving average of $446.98. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $620.00.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Analysts Set New Price Targets

TMO has been the topic of a number of recent research reports. UBS Group upped their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Robert W. Baird increased their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, September 7th. Raymond James Financial restated an "outperform" rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a report on Friday, July 11th. Fifteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $583.53.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 in the last three months. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.